Literature DB >> 6796250

Renal disease after mitomycin C therapy.

W T Hanna, S Krauss, R F Regester, W M Murphy.   

Abstract

Fourteen patients with adenocarcinoma of the gastrointestinal tract and pancreas treated with mitomycin C(MMC) and 5-fluorouracil (5-FU) had renal impairment 6-11 months from the beginning of MMC therapy. Two clinical entities were recognized: an acute fulminating renal failure that was rapidly fatal and a chronic slowly progressive renal impairment. The first entity showed a microangiopathic hemolytic profile with anemia, thrombocytopenia, and erythrocyte fragmentation. Light microscopy and electron microscopy examination of the kidney revealed a primary vascular disease with musculomucoid intimal hyperplasia of arteries and rare fibrin thrombi in arterioles. Interstitial fibrosis, tubular atrophy, and widespread glomerular necrosis were also seen. The disease was ultimately fatal within three to four weeks. The second entity showed a chronic course of renal failure with similar pathologic findings but less pronounced, and a microangiopathic hemolysis was absent. The course in the second group was ultimately fatal between three to eight months.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 6796250     DOI: 10.1002/1097-0142(19811215)48:12<2583::aid-cncr2820481208>3.0.co;2-6

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  12 in total

Review 1.  Guide to drug dosage in renal failure.

Authors:  W M Bennett
Journal:  Clin Pharmacokinet       Date:  1988-11       Impact factor: 6.447

2.  Induction of prophages of enterohemorrhagic Escherichia coli O157:H7 with norfloxacin.

Authors:  A Matsushiro; K Sato; H Miyamoto; T Yamamura; T Honda
Journal:  J Bacteriol       Date:  1999-04       Impact factor: 3.490

3.  Glomerular tuft ballooning in mitomycin-C-induced renal impairment.

Authors:  H Shiiki; K Dohi; H Nishioka; T Matsuda; M Kanauchi; H Uyama; H Ishikawa; T Watanabe
Journal:  Virchows Arch A Pathol Anat Histopathol       Date:  1992

4.  Cardiotoxicity of mitomycin A, mitomycin C, and seven N7 analogs in vitro.

Authors:  R T Dorr; N G Shipp; J D Liddil; B S Iyengar; K R Kunz; W A Remers
Journal:  Cancer Chemother Pharmacol       Date:  1992       Impact factor: 3.333

5.  Mitomycin-induced hemolytic uremic kidney. An experimental model in the rat.

Authors:  V Cattell
Journal:  Am J Pathol       Date:  1985-10       Impact factor: 4.307

6.  Severe glomerular mesangiolysis in a patient with rectal adenocarcinoma treated with cytotoxic drugs.

Authors:  G Mazzucco; G Fornari; G Monga
Journal:  Virchows Arch A Pathol Anat Histopathol       Date:  1982

7.  Regulation of the Shiga-like toxin II operon in Escherichia coli.

Authors:  I Mühldorfer; J Hacker; G T Keusch; D W Acheson; H Tschäpe; A V Kane; A Ritter; T Olschläger; A Donohue-Rolfe
Journal:  Infect Immun       Date:  1996-02       Impact factor: 3.441

8.  Hemolytic uremic syndrome in a patient on cis-platinum, vinblastine and bleomycin.

Authors:  J van der Meer; E G de Vries; R Vriesendorp; P H Willemse; A J Donker; J G Aalders
Journal:  J Cancer Res Clin Oncol       Date:  1985       Impact factor: 4.553

9.  Haemolytic-uraemic syndrome complicating long-term mitomycin C and 5-fluorouracil therapy for gastric carcinoma.

Authors:  J Crocker; E L Jones
Journal:  J Clin Pathol       Date:  1983-01       Impact factor: 3.411

Review 10.  Anticancer drug-induced kidney disorders.

Authors:  P E Kintzel
Journal:  Drug Saf       Date:  2001-01       Impact factor: 5.228

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.